<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fluorouracil (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fluorouracil (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fluorouracil (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9131" href="/d/html/9131.html" rel="external">see "Fluorouracil (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="11684" href="/d/html/11684.html" rel="external">see "Fluorouracil (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8100806"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Adrucil [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10493258"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Antimetabolite</span></li></ul></div>
<div class="block dop drugH1Div" id="F49321696"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose, frequency, number of doses, and/or start date may vary by protocol and treatment phase. Refer to individual protocols.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ce17d3e0-5a62-4c43-92d4-7e6e951d1d27">Hepatoblastoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatoblastoma:</b> Limited data available: Infants, Children, and Adolescents: IV: 600 mg/m<sup>2</sup>/dose every 3 weeks on day 2 or 3 (in combination with cisplatin, vincristine ± doxorubicin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8380296','lexi-content-ref-10894865','lexi-content-ref-24052132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8380296','lexi-content-ref-10894865','lexi-content-ref-24052132'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1c37071b-eb52-4503-845d-b0fed618a118">Nasopharyngeal carcinoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nasopharyngeal carcinoma:</b> Limited data available: Children ≥8 years and Adolescents: Continuous IV infusion: 1,000 mg/m<sup>2</sup>/day for 3 to 5 days every 3 to 4 weeks for 3 to 4 cycles (in combination with other chemotherapy agents)(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22359313','lexi-content-ref-21918965','lexi-content-ref-15999363','lexi-content-ref-15641027']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22359313','lexi-content-ref-21918965','lexi-content-ref-15999363','lexi-content-ref-15641027'])">Ref</a></span>)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51130550"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific dosage adjustments available; refer to protocols. Based on experience in adult patients, extreme caution should be used in patients with renal impairment and dosing adjustment is suggested.</p></div>
<div class="block dohp drugH1Div" id="F51130551"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;">There are no pediatric specific dosage adjustments available; refer to protocols. Based on experience in adult patients, extreme caution should be used in patients with hepatic impairment and dosing adjustment is suggested.</p></div>
<div class="block doa drugH1Div" id="F8100893"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9131" href="/d/html/9131.html" rel="external">see "Fluorouracil (systemic): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1dbb6447-35bc-49b2-826f-4e8b8b0cdaa6">Anal carcinoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anal carcinoma (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Localized disease: </i>
<b>IV:</b> 1,000 mg/m<sup>2</sup>/day continuous infusion days 1 to 4 (total dose is 4,000 mg/m<sup>2</sup>) and days 29 to 32 (total dose is 4,000 mg/m<sup>2</sup>) (in combination with mitomycin and radiation therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18430910','lexi-content-ref-8823332']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18430910','lexi-content-ref-8823332'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Advanced or metastatic disease:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>In combination with cisplatin: </i>
<b>IV:</b> 750 mg/m<sup>2</sup>/day continuous infusion days 1 to 5 (total dose/cycle is 3,750 mg/m<sup>2</sup>) every 4 weeks (in combination with cisplatin); patients received a median of 4 cycles in the study (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25373735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25373735'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>FOLFCIS regimen:</i>
<b>IV:</b> 400 mg/m<sup>2</sup> bolus on day 1, followed by 1,000 mg/m<sup>2</sup>/day continuous infusion days 1 and 2 (total dose/cycle [bolus and continuous infusion] is 2,400 mg/m<sup>2</sup>) every 14 days until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30316684']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30316684'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="70eab7a6-b58d-487c-8f61-229bd7e67a11">Biliary tract cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Biliary tract cancer, advanced (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFOX regimen:</i>
<b>IV</b>: 400 mg/m<sup>2</sup> bolus on day 1, followed by 2,400 mg/m<sup>2</sup> over 46 hours (as a continuous infusion) every 2 weeks (total dose/cycle [bolus and continuous infusion] is 2,800 mg/m<sup>2</sup>; in combination with levoleucovorin and oxaliplatin) for up to 12 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33798493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33798493'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="42c64b45-8d4d-40d6-b00b-44a54ca32803">Bladder cancer, muscle-invasive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bladder cancer, muscle-invasive (off-label use):</b>
<b>IV:</b> 500 mg/m<sup>2</sup>/day continuous infusion during radiation therapy fractions 1 to 5 and 16 to 20 (total dose/each 5-day course is 2,500 mg/m<sup>2</sup>; in combination with mitomycin and radiation therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22512481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22512481'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f629398a-17b2-4a1a-8177-10deeef034f4">Breast cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CEF or FEC regimen:</i>
<b>IV: </b>500 mg/m<sup>2</sup> on days 1 and 8 every 28 days (in combination with cyclophosphamide and epirubicin) for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9704715']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9704715'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CMF regimen:</i>
<b>IV: </b>600 mg/m<sup>2</sup> on days 1 and 8 every 28 days (in combination with cyclophosphamide and methotrexate) for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9653488','lexi-content-ref-9704715']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9653488','lexi-content-ref-9704715'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Breast cancer, early, HER2-positive:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>FEC-THP regimen: <b>IV:</b></i> 500 mg/m<sup>2 </sup>on day 1 every 3 weeks (in combination with epirubicin and cyclophosphamide) as neoadjuvant therapy for 3 cycles, followed by 3 cycles of neoadjuvant docetaxel, trastuzumab, and pertuzumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23704196']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23704196'])">Ref</a></span>). Refer to protocol for further information.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>THP-FEC-H regimen: <b>IV:</b></i>600 mg/m<sup>2 </sup>on day 1 every 3 weeks (in combination with epirubicin and cyclophosphamide) as adjuvant therapy for 3 cycles, followed by trastuzumab to complete 1 year of treatment; neoadjuvant trastuzumab, pertuzumab, and docetaxel were administered for 4 cycles prior to surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22153890']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22153890'])">Ref</a></span>). Refer to protocol for further information.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5a4717b7-7018-4db7-91b6-7467d949c9f0">Cervical cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cervical cancer (off-label use):</b>
<b>IV:</b> 1,000 mg/m<sup>2</sup>/day continuous infusion days 1 to 4 (total dose/cycle is 4,000 mg/m<sup>2</sup>; in combination with cisplatin and radiation therapy) every 3 weeks for 3 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14990643','lexi-content-ref-10202164']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14990643','lexi-content-ref-10202164'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b39dab5-f5ca-4dde-9071-ab66ae1272b6">Colorectal cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Colorectal cancer: IV:</b> 400 mg/m<sup>2</sup> bolus on day 1, followed by 2,400 to 3,000 mg/m<sup>2</sup> over 46 hours (as a continuous infusion) every 2 weeks (in combination with leucovorin ± either oxaliplatin or irinotecan) <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Preoperative chemoradiation (in patients with clinical stage II or III rectal cancer):</i>
<b>IV: </b>225 mg/m<sup>2</sup>/day continuous infusion 5 days per week for a total of 5 weeks (total dose/week is 1,125 mg/m<sup>2</sup>; in combination with radiation therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24799484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24799484'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Roswell Park regimen:</i>
<b>IV: </b>500 mg/m<sup>2</sup> (bolus) on days 1, 8, 15, 22, 29, and 36 (1 hour after the start of leucovorin) every 8 weeks (in combination with leucovorin) for 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16314627']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16314627'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFOX regimens:</i>
<b>Note: </b>Multiple FOLFOX variations exist and may be administered in combination with other agents for the treatment of colorectal cancer. FOLFOX regimens may also be administered in combination with bevacizumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18421053','lexi-content-ref-24608198']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18421053','lexi-content-ref-24608198'])">Ref</a></span>), cetuximab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28632865']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28632865'])">Ref</a></span>), or panitumumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24718886','lexi-content-ref-20921465']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24718886','lexi-content-ref-20921465'])">Ref</a></span>). Refer to institutional guidelines and/or protocols for further information.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>FOLFOX6 and mFOLFOX6 regimen:</i>
<b>IV: </b>400 mg/m<sup>2</sup> bolus on day 1, followed by 2,400 mg/m<sup>2</sup> over 46 hours (as a continuous infusion) every 2 weeks (in combination with leucovorin and oxaliplatin) until disease progression or unacceptable toxicity occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12177775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12177775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>mFOLFOX7 regimen:</i>
<b>IV: </b>2,400 mg/m<sup>2</sup> over 46 hours (as a continuous infusion) every 2 weeks (in combination with leucovorin and oxaliplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24608198']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24608198'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFIRI regimen:</i>
<b>IV: </b>400 mg/m<sup>2</sup> bolus on day 1, followed by 2,400 mg/m<sup>2</sup> over 46 hours (as a continuous infusion) every 2 weeks (in combination with leucovorin and irinotecan) until disease progression or unacceptable toxicity occurs; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10658525']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10658525'])">Ref</a></span>). <b>Note: </b>FOLFIRI regimens may be also administered in combination with bevacizumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17947725']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17947725'])">Ref</a></span>), cetuximab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19339720','lexi-content-ref-21502544']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19339720','lexi-content-ref-21502544'])">Ref</a></span>), panitumumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20921462']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20921462'])">Ref</a></span>), ramucirumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25877855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25877855'])">Ref</a></span>), or ziv-aflibercept (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22949147']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22949147'])">Ref</a></span>); refer to protocols for further information.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFOXIRI regimen:</i>
<b>IV: </b>3,200 mg/m<sup>2</sup> over 48 hours (as a continuous infusion) every 14 days (in combination with leucovorin, oxaliplatin, and irinotecan) until disease progression or unacceptable toxicity up to a maximum of 12 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17470860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17470860'])">Ref</a></span>); may also be used in combination with bevacizumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26338525','lexi-content-ref-25337750']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26338525','lexi-content-ref-25337750'])">Ref</a></span>); refer to protocol for further information <b>or </b>3,000 mg/m<sup>2</sup> over 48 hours (as a continuous infusion) every 14 days (in combination with leucovorin, oxaliplatin, irinotecan, and panitumumab) until disease progression or resection for up to a maximum of 12 preoperative cycles in patients with wild-type RAS metastatic colorectal cancer; after resection, patients received the same regimen as adjuvant therapy for a total of 12 perioperative cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31609637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31609637'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FLOX regimen (off-label dosing)</i>
<i>:</i>
<b>IV: </b>500 mg/m<sup>2</sup> bolus on days 1, 8, 15, 22, 29, and 36 (1 hour after the start of leucovorin) every 8 weeks (in combination with leucovorin and oxaliplatin) for 3 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17470851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17470851'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adjuvant therapy duration; completely resected stage 3 colon cancer (off label):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Low risk (T1, T2, or T3 and N1):</i> A duration of therapy of 3 or 6 months of fluoropyrimidine/oxaliplatin-based adjuvant chemotherapy may be offered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30986117']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30986117'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>High risk (T4 and/or N2):</i> A duration of therapy of 6 months of fluoropyrimidine/oxaliplatin-based adjuvant chemotherapy should be offered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30986117']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30986117'])">Ref</a></span>). In a pooled analysis of 6 phase 3 studies, superior disease-free survival has been demonstrated with 6 months (compared to 3 months) of adjuvant FOLFOX therapy in the subgroup of patients with T4 and/or N2 stage 3 colon cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29590544']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29590544'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e50dc227-3f50-48ae-aba5-898bd2fb9c33">Esophageal cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophageal cancer (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CF regimen (esophageal or gastroesophageal junction cancer):</i>
<b>IV:</b> 1,000 mg/m<sup>2</sup>/day continuous infusion days 1 to 4 (total dose/cycle is 4,000 mg/m<sup>2</sup>) every 28 days (in combination with cisplatin and concurrent radiation) for 4 cycles, followed by 2 additional cycles after a 4-week rest following completion of radiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11870157']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11870157'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup>/day continuous infusion days 1 to 4 (total dose is 4,000 mg/m<sup>2</sup>) and days 29 to 32 (total dose is 4,000 mg/m<sup>2</sup>) of a 35-day treatment cycle (preoperative chemoradiation; in combination with cisplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18309943']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18309943'])">Ref</a></span>) <b>or </b>1,000 mg/m<sup>2</sup>/day continuous infusion days 1 to 4 (total dose/cycle is 4,000 mg/m<sup>2</sup>) every 3 weeks for 2 cycles (neoadjuvant chemotherapy prior to surgery; in combination with cisplatin; for adenocarcinoma) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28784312']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28784312'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FLO regimen (locally advanced or metastatic gastroesophageal junction adenocarcinoma):</i>
<b>IV:</b> 2,600 mg/m<sup>2</sup> continuous infusion over 24 hours on day 1 every 2 weeks (in combination with leucovorin and oxaliplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18349393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18349393'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FLOT regimen (locally advanced, resectable gastroesophageal junction adenocarcinoma):</i>
<b>IV: </b>2,600 mg/m<sup>2</sup> continuous infusion over 24 hours on day 1 every 2 weeks (in combination with leucovorin, oxaliplatin, and docetaxel) for 4 preoperative cycles and 4 postoperative cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30982686']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30982686'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFOX4 regimen (chemoradiotherapy for locally advanced, recurrent, or metastatic disease): </i>
<b>IV: </b>400 mg/m<sup>2</sup> bolus, followed by 600 mg/m<sup>2</sup> over 22 hours, repeated for 2 consecutive days (total dose/cycle [bolus and continuous infusion] is 2,000 mg/m<sup>2</sup>) every 2 weeks, in combination with leucovorin and oxaliplatin and radiation for 3 cycles, then without radiation for 3 more cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20940718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20940718'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFOX/nivolumab (unresectable advanced or metastatic esophageal or gastroesophageal junction adenocarcinoma): </i>
<b>IV: </b>400 mg/m<sup>2</sup> bolus on day 1, followed by 1,200 mg/m<sup>2</sup>/day on days 1 and 2 (as a continuous infusion) every 2 weeks (total dose/cycle [bolus and continuous infusion] is 2,800 mg/m<sup>2</sup>; in combination with leucovorin, oxaliplatin, and nivolumab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34102137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34102137'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>mFOLFOX6 (metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or gastroesophageal junction): </i>
<b>IV: </b>400 mg/m<sup>2</sup> bolus on day 1, followed by 2,400 mg/m<sup>2</sup> over 46 to 48 hours (as a continuous infusion) every 2 weeks (total dose/cycle [bolus and continuous infusion] is 2,800 mg/m<sup>2</sup>; in combination with leucovorin and oxaliplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27382098']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27382098'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nivolumab/cisplatin/fluorouracil (esophageal squamous cell carcinoma): </i>
<b>IV:</b> 800 mg/m<sup>2</sup>/day as a continuous infusion on days 1 to 5 (total dose/cycle is 4,000 mg/m<sup>2</sup>) every 4 weeks until disease progression or unacceptable toxicity; patients could continue nivolumab for up to 2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35108470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35108470'])">Ref</a></span>). Refer to protocol for further details.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pembrolizumab/cisplatin/fluorouracil (esophageal or gastroesophageal junction cancer): </i>
<b>IV: </b>800 mg/m<sup>2</sup>/day as a continuous infusion on days 1 to 5 every 3 weeks (total dose/cycle is 4,000 mg/m<sup>2</sup>); continue pembrolizumab and fluorouracil until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34454674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34454674'])">Ref</a></span>). Refer to protocol for further details.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pembrolizumab/trastuzumab/cisplatin/fluorouracil (HER2-positive gastroesophageal junction adenocarcinoma):</i>
<b>IV: </b>800 mg/m<sup>2</sup>/day as a continuous infusion on days 1 to 5 every 3 weeks (total dose/cycle is 4,000 mg/m<sup>2</sup>); continue until disease progression or unacceptable toxicity or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34912120']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34912120'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>TCF or DCF or mDCF regimen (advanced gastroesophageal junction adenocarcinoma):</i>
<b>IV: </b>400 mg/m<sup>2</sup> bolus on day 1, followed by 1,000 mg/m<sup>2</sup>/day as a continuous infusion on days 1 and 2 every 2 weeks (total dose/cycle [bolus and continuous infusion] is 2,400 mg/m<sup>2</sup>; in combination with docetaxel, leucovorin, and cisplatin; mDCF regimen) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26438119']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26438119'])">Ref</a></span>) <b>or</b> 750 mg/m<sup>2</sup>/day continuous infusion days 1 to 5 (total dose/cycle is 3,750 mg/m<sup>2</sup>) every 3 weeks (in combination with docetaxel and cisplatin) until disease progression or unacceptable toxicity occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17664468','lexi-content-ref-17075117']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17664468','lexi-content-ref-17075117'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ToGA regimen (HER2-positive; locally advanced, recurrent, or metastatic gastroesophageal junction adenocarcinoma):</i>
<b>IV: </b>800 mg/m<sup>2</sup>/day continuous infusion days 1 to 5 (total dose/cycle is 4,000 mg/m<sup>2</sup>) every 3 weeks (in combination with cisplatin and trastuzumab) for 6 cycles; continue trastuzumab until disease progression or unacceptable toxicity occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20728210']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20728210'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment of advanced or metastatic disease:</i> Treatment with doublet, rather than triplet, chemotherapy may be preferred in the palliative setting due to increased toxicity (without clear benefit) with triplet regimens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35914638']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35914638'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0941e1ee-82d0-48a1-a4ca-aa05a3115959">Gastric cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric cancer:</b>
<b>IV:</b> Continuous infusion (as part of a platinum-containing regimen); the dose, duration, and frequency of each cycle varies based on the regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FLO regimen (locally advanced or metastatic gastric adenocarcinoma):</i>
<b>IV:</b> 2,600 mg/m<sup>2</sup> continuous infusion over 24 hours on day 1 every 2 weeks (in combination with leucovorin and oxaliplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18349393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18349393'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FLOT regimen (locally advanced, resectable gastric adenocarcinoma):</i>
<b>IV: </b>2,600 mg/m<sup>2</sup> continuous infusion over 24 hours on day 1 every 2 weeks (in combination with leucovorin, oxaliplatin, and docetaxel) for 4 preoperative cycles and 4 postoperative cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30982686']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30982686'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFOX/nivolumab (unresectable advanced or metastatic gastric adenocarcinoma): </i>
<b>IV: </b>400 mg/m<sup>2</sup> bolus on day 1, followed by 1,200 mg/m<sup>2</sup>/day on days 1 and 2 (as a continuous infusion) every 2 weeks (total dose/cycle [bolus and continuous infusion] is 2,800 mg/m<sup>2</sup>; in combination with leucovorin, oxaliplatin, and nivolumab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34102137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34102137'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pembrolizumab/trastuzumab/cisplatin/fluorouracil (HER2-positive gastric adenocarcinoma):</i>
<b>IV: </b>800 mg/m<sup>2</sup>/day as a continuous infusion on days 1 to 5 every 3 weeks (total dose/cycle is 4,000 mg/m<sup>2</sup>); continue until disease progression or unacceptable toxicity or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34912120']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34912120'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>TCF or DCF or mDCF regimen (advanced gastric adenocarcinoma):</i>
<b>IV:</b> 400 mg/m<sup>2</sup> bolus on day 1, followed by 1,000 mg/m<sup>2</sup>/day as a continuous infusion on days 1 and 2 every 2 weeks (total dose/cycle [bolus and continuous infusion] is 2,400 mg/m<sup>2</sup>; in combination with docetaxel, leucovorin, and cisplatin; mDCF regimen) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26438119']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26438119'])">Ref</a></span>) <b>or </b>750mg/m<sup>2</sup>/day continuous infusion days 1 to 5 (total dose/cycle is 3,750 mg/m<sup>2</sup>) every 3 weeks (in combination with docetaxel and cisplatin) until disease progression or unacceptable toxicity occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17664468','lexi-content-ref-17075117']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17664468','lexi-content-ref-17075117'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ToGA regimen (HER2-positive; locally advanced, recurrent, or metastatic gastric adenocarcinoma):</i>
<b>IV: </b>800 mg/m<sup>2</sup>/day continuous infusion days 1 to 5 (total dose/cycle is 4,000 mg/m<sup>2</sup>) every 3 weeks (in combination with cisplatin and trastuzumab) for 6 cycles; continue trastuzumab until disease progression or unacceptable toxicity occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20728210']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20728210'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Treatment of advanced or metastatic disease:</i> Treatment with doublet, rather than triplet, chemotherapy is preferred in the palliative setting due to increased toxicity (without clear benefit) with triplet regimens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32861308']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32861308'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="53dcc03b-4107-4eb4-b376-386985faf193">Glaucoma surgery, adjunctive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Glaucoma surgery, adjunctive therapy (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intraoperative topical application:</i>
<b>Ophthalmic: </b>Apply sponge soaked in fluorouracil 50 mg/mL for 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26545176','lexi-content-ref-18930550','lexi-content-ref-12383808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26545176','lexi-content-ref-18930550','lexi-content-ref-12383808'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postoperative subconjunctival injection:</i>
<b>Ophthalmic: </b>5 mg once daily for 10 days <b>or </b>5 mg once daily for 1 week, then every other day the next week for a total of 10 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26545176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26545176'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="459ff2f1-bdf2-4201-9248-bf05505ff1c7">Head and neck cancer, advanced, squamous cell</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Head and neck cancer, advanced, squamous cell (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Platinum-Fluorouracil (CF) regimen:</i>
<b>IV: </b>1,000 mg/m<sup>2</sup>/day continuous infusion days 1 to 4 (total dose/cycle is 4,000 mg/m<sup>2</sup>) every 3 weeks (in combination with cisplatin) for at least 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15908667']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15908667'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup>/day continuous infusion days 1 to 4 (total dose/cycle is 4,000 mg/m<sup>2</sup>) every 4 weeks (in combination with carboplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1634913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1634913'])">Ref</a></span>) <b>or</b> 600 mg/m<sup>2</sup>/day continuous infusion days 1 to 4, 22 to 25, and 43 to 46 (total dose for each 4-day course is 2,400 mg/m<sup>2</sup>; in combination with carboplatin and radiation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22261362','lexi-content-ref-14657228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22261362','lexi-content-ref-14657228'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>TPF regimen:</i>
<b>IV: </b>1,000 mg/m<sup>2</sup>/day continuous infusion days 1 to 4 (total dose/cycle is 4,000 mg/m<sup>2</sup>) every 3 weeks (in combination with docetaxel and cisplatin) for 3 cycles, and followed by chemoradiotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17960013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17960013'])">Ref</a></span>) <b>or</b> 750 mg/m<sup>2</sup>/day continuous infusion days 1 to 5 (total dose/cycle is 3,750 mg/m<sup>2</sup>) every 3 weeks (in combination with docetaxel and cisplatin) for up to 4 cycles, followed by radiation in patients without progressive disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17960012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17960012'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Platinum, fluorouracil, and cetuximab regimen:</i>
<b>IV: </b>1,000 mg/m<sup>2</sup>/day continuous infusion days 1 to 4 (total dose/cycle is 4,000 mg/m<sup>2</sup>) every 3 weeks (in combination with cetuximab and either cisplatin or carboplatin) for a total of up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18784101']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18784101'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pembrolizumab-fluorouracil-platinum regimen: </i>
<b>IV: </b>1,000 mg/m<sup>2</sup>/day continuous infusion days 1 to 4 (total dose/cycle is 4,000 mg/m<sup>2</sup>) every 3 weeks (in combination with either carboplatin or cisplatin and pembrolizumab) for 6 cycles, followed by up to 24 months of pembrolizumab monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31679945']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31679945'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6d693e0a-c547-4d35-95bf-c857d87f0dfc">Neuroendocrine tumors: Pancreatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroendocrine tumors: Pancreatic (off-label use): IV:</b> 400 mg/m<sup>2</sup>/day (bolus) days 1 to 5 every 28 days (in combination with doxorubicin and streptozocin) for at least 4 cycles and until disease progression or unacceptable toxicity occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15570077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15570077'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c856e2c-2f61-4353-a4d1-5e5b8945caaa">Pancreatic cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic cancer:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Potentially curable disease, adjuvant therapy: </i>
<b>Note:</b> American Society of Clinical Oncology (ASCO) guidelines recommend 6 months of adjuvant therapy; if preoperative chemotherapy therapy was received, a total of 6 months of adjuvant therapy (including the preoperative regimen) is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31180816']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31180816'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>mFOLFIRINOX regimen: </i>
<b>IV: </b>2,400 mg/m<sup>2</sup> as a continuous infusion over 46 hours every 14 days (in combination with leucovorin, irinotecan, and oxaliplatin) for 24 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30575490']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30575490'])">Ref</a></span>). According to ASCO guidelines, mFOLFIRINOX is the preferred first-line adjuvant regimen for potentially curable disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31180816']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31180816'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Chemoradiation therapy (off-label dosing):</i>
<b>IV: </b>250 mg/m<sup>2</sup>/day continuous infusion for 3 weeks prior to and then throughout radiation therapy; an additional 12 weeks of fluorouracil (as a continuous infusion, 4 weeks on and 2 weeks off for 2 cycles) was administered beginning 3 to 5 weeks after completion of chemoradiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18319412']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18319412'])">Ref</a></span>). <b>Note: </b>According to ASCO guidelines for potentially curable pancreatic cancer, adjuvant chemoradiation therapy may be considered for patients not receiving preoperative therapy and who present with positive margins (microscopically) following surgery and/or node-positive disease after completion of 4 to 6 months of systemic adjuvant chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31180816']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31180816'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Advanced or metastatic disease:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Fluorouracil with irinotecan (liposomal):</i>
<b>I</b>
<b>V: </b>2,400 mg/m<sup>2</sup> (as a continuous infusion) over 46 hours every 14 days (in combination with leucovorin and irinotecan [liposomal]) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26615328']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26615328'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>FOLFIRINOX regimen: </i>
<b>IV: </b>400 mg/m<sup>2</sup> bolus on day 1, followed by 2,400 mg/m<sup>2</sup> (as a continuous infusion) over 46 hours every 14 days (in combination with leucovorin, irinotecan, and oxaliplatin) until disease progression or unacceptable toxicity occurs for a recommended 12 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21561347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21561347'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>mFOLFOX regimen (second-line therapy):</i>
<b>IV:</b> 2,000 mg/m<sup>2</sup> (as a continuous infusion) over 46 hours every 2 weeks (in combination with leucovorin and oxaliplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19826418']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19826418'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>OFF regimen (second-line therapy):</i>
<b>IV: </b>2,000 mg/m<sup>2</sup>/day continuous infusion over 24 hours on days 1, 8, 15, and 22 every 6 weeks (in combination with oxaliplatin and leucovorin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24982456','lexi-content-ref-21565490']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24982456','lexi-content-ref-21565490'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="25ba6063-c827-4ece-b14d-6c38bbd89635">Penile cancer, advanced, squamous cell</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Penile cancer, advanced, squamous cell (off-label use):</b>
<b>IV:</b> 800 to 1,000 mg/m<sup>2</sup>/day continuous infusion for 4 days (total dose/cycle is 3,200 to 4,000 mg/m<sup>2</sup>) every 21 days (in combination with cisplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22958571']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22958571'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup>/day continuous infusion on days 1 to 4 (total dose is 4,000 mg/m<sup>2</sup>) and days 29 to 32 (total dose is 4,000 mg/m<sup>2</sup>) (in combination with mitomycin and radiation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32335061']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32335061'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="80e1258c-674d-41d4-a1b2-d3be69bcf8cf">Small bowel adenocarcinoma, advanced unresectable or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Small bowel adenocarcinoma, advanced unresectable or metastatic (off-label use): Note: </b>Ampullary adenocarcinomas were excluded from these studies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28536826','lexi-content-ref-20223786','lexi-content-ref-21425142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28536826','lexi-content-ref-20223786','lexi-content-ref-21425142'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFIRI regimen (following progression on a platinum-based regimen): </i>
<b>IV: </b>400 mg/m<sup>2</sup> bolus on day 1, followed by 2,400 mg/m<sup>2</sup> over 46 hours (as a continuous infusion) every 2 weeks (total dose/cycle [bolus and continuous infusion] is 2,800 mg/m<sup>2</sup>; in combination with leucovorin and irinotecan) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21425142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21425142'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>mFOLFOX or FOLFOX regimen:</i>
<b>IV:</b> 400 mg/m<sup>2</sup> bolus on day 1, followed by 2,400 mg/m<sup>2</sup> over 46 hours (as a continuous infusion) every 2 weeks (total dose/cycle [bolus and continuous infusion] is 2,800 mg/m<sup>2</sup>; in combination with leucovorin and oxaliplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28536826','lexi-content-ref-20223786']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28536826','lexi-content-ref-20223786'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="349e5755-662f-421b-bb2c-53b7293e5f4c">Unknown primary cancer, squamous cell</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Unknown primary cancer, squamous cell (off-label use): IV:</b> 750 mg/m<sup>2</sup>/day continuous infusion for 5 days (total dose/cycle is 3,750 mg/m<sup>2</sup>) every 21 days (in combination with docetaxel and cisplatin) for 3 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19318632']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19318632'])">Ref</a></span>) <b>or</b> 500 mg/m<sup>2</sup>/day continuous infusion for 5 days (total dose/cycle is 2,500 mg/m<sup>2</sup>) every 21 days (in combination with paclitaxel and cisplatin) for 3 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16275937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16275937'])">Ref</a></span>) <b>or </b>400 mg/m<sup>2</sup> bolus on day 1 followed by 1,200 mg/m<sup>2</sup>/day continuous infusion for 2 days (over 46 hours) every 2 weeks (in combination with leucovorin and oxaliplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12177775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12177775'])">Ref</a></span>) <b>or </b>700 mg/m<sup>2</sup>/day continuous infusion for 5 days (total dose/cycle is 3,500 mg/m<sup>2</sup>) (in combination with cisplatin) every 28 days until disease progression or unacceptable toxicity occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17848753']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17848753'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5d3f43c7-d977-4f7d-9c5c-4c45d94e9ec5">Vulvar cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vulvar cancer, advanced (off-label use): IV:</b> 1,000 mg/m<sup>2</sup>/day on days 1 to 4 (total dose/cycle is 4,000 mg/m<sup>2</sup>; in combination with cisplatin and radiation therapy) every 28 days for 2 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9747823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9747823'])">Ref</a></span>) <b>or</b> 750 mg/m<sup>2</sup>/day continuous infusion days 1 to 5 (total dose/cycle is 3,750 mg/m<sup>2</sup>) every 14 days for 2 cycles (in combination with concomitant radiation and mitomycin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8641609']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8641609'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991160"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Kenar D. Jhaveri, MD; Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Although only 5% to 20% of fluorouracil is excreted unchanged by the kidney, the intermediate metabolite, alpha-fluoro-beta-alanine (FBAL), accumulates in kidney impairment. FBAL is converted to fluoro mono acetate (FMA), which is associated with neurotoxicity. It has been hypothesized that accumulation of FBAL and FMA may contribute to hyperammonemic encephalopathy reported with the use of fluorouracil (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kitai.1','lexi-content-ref-28204913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kitai.1','lexi-content-ref-28204913'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: IV: </b>No dosage adjustment necessary for any degree of kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12853359','lexi-content-ref-20118214','lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12853359','lexi-content-ref-20118214','lexi-content-ref-30942181'])">Ref</a></span>). <b>Note: </b>Monitor patients with advanced kidney disease (eg, eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>) closely for hyperammonemic encephalopathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b>
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Fluorouracil (parent drug) is not significantly dialyzable; however, the metabolite, FBAL, may be substantially removed by dialysis (extraction ratio 0.73 to 0.84) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11840401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11840401'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> No dosage adjustment necessary. When scheduled dose falls on a hemodialysis day, administer after hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30304984','lexi-content-ref-29531838','lexi-content-ref-20118214','lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30304984','lexi-content-ref-29531838','lexi-content-ref-20118214','lexi-content-ref-30942181'])">Ref</a></span>). <b>Note:</b> Monitor patients closely for the development of hyperammonemic encephalopathy associated with FBAL accumulation in patients with end-stage kidney disease. Removal of FBAL by hemodialysis may be effective in preventing or treating hyperammonemia associated with elevated FBAL concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20118214','lexi-content-ref-33011861','lexi-content-ref-11840401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20118214','lexi-content-ref-33011861','lexi-content-ref-11840401'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b>
<b>IV:</b> Not significantly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26687170']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26687170'])">Ref</a></span>): No dosage adjustment necessary. <b>Note: </b>Monitor patients closely for hyperammonemic encephalopathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): IV:</b> No dosage adjustment necessary. When scheduled dose falls on a PIRRT day, administer after PIRRT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988522"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution. The following adjustments have been suggested:</p>
<p style="text-indent:-2em;margin-left:2em;">Mild or moderate impairment (without concomitant renal impairment): No need for dose adjustment is expected (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use is not recommended; avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16473644','lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16473644','lexi-content-ref-30942181'])">Ref</a></span>).</p></div>
<div class="block adr drugH1Div" id="F8100834"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (Steger 2012), angina pectoris (Steger 2012), cardiac arrhythmia (Steger 2012), cardiotoxicity (including takotsubo syndrome) (McGlinchey 2001; Steen 2023), chest pain (Pottage 1978), coronary artery vasospasm (Connolly 2010), heart failure (Fakhri 2016), ischemic heart disease (Steger 2012), pericarditis (Killu 2011), thrombophlebitis, vein discoloration, ventricular fibrillation (Fradley 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Changes in nails (including nail loss), palmar-plantar erythrodysesthesia, skin fissure, skin photosensitivity, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, dysgeusia (Syed 2016), esophagopharyngitis, gastrointestinal ulcer, nausea, stomatitis, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia, pancytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Euphoria, headache, hyperammonemic encephalopathy (Kitai 2016; Nishikawa 2017), leukoencephalopathy (Hemachudha 2023), neurological abnormality (including ataxia, cerebellar syndrome [acute], confusion, disorientation)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Lacrimal stenosis, lacrimation, nystagmus disorder, photophobia, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis</p></div>
<div class="block coi drugH1Div" id="F8100831"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer’s US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<i>Canadian labeling:</i> Known hypersensitivity to fluorouracil or any component of the formulation; debilitated patients; poor nutritional state; depressed bone marrow function following radiotherapy or therapy with other antineoplastic agents; potentially serious infections.</p></div>
<div class="block war drugH1Div" id="F8100832"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Fluorouracil can cause severe and fatal hematologic toxicity (neutropenia, thrombocytopenia, and anemia). The neutrophil nadir usually occurs between 9 to 14 days after administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiotoxicity: Based on postmarketing reports, fluorouracil may cause cardiotoxicity (angina, MI/ischemia, arrhythmia, and heart failure). Risk factors for cardiotoxicity include continuous infusion administration (versus IV bolus) and coronary artery disease. The risks of resuming fluorouracil in patients with resolved cardiotoxicity have not been established. In a scientific statement from the American Heart Association, fluorouracil has been determined to be an agent that may either cause reversible direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate/major) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicity: Fluorouracil is associated with severe diarrhea. Mucositis, stomatitis, or esophagopharyngitis (which may lead to mucosal sloughing or ulceration) may occur with fluorouracil. The incidence of mucositis is reported to be higher with IV bolus fluorouracil administration (vs continuous infusion).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hand-foot syndrome: Fluorouracil is associated with palmar-plantar erythrodysesthesia (hand-foot syndrome; HFS). Symptoms of HFS include a tingling sensation, pain, swelling, erythema with tenderness, and desquamation. HFS occurs more commonly when fluorouracil is administered as a continuous infusion (compared to IV bolus) and has been reported to occur more frequently in patients with prior chemotherapy exposure. The onset of HFS is usually after 8 to 9 weeks of fluorouracil, although may occur earlier.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperammonemic encephalopathy: Fluorouracil may result in hyperammonemic encephalopathy in the absence of liver disease or other identifiable cause (postmarketing reports). The onset of hyperammonemic encephalopathy signs/symptoms (altered mental status, confusion, disorientation, coma, or ataxia, in the presence of concomitant elevated serum ammonia level) was within 72 hours after fluorouracil infusion initiation. The risks of resuming fluorouracil in patients with resolved hyperammonemic encephalopathy have not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurotoxicity: Fluorouracil may cause neurologic toxicity, including acute cerebellar syndrome and other neurologic events (postmarketing reports). Neurologic symptoms included confusion, disorientation, ataxia, or visual disturbances. There are insufficient data on the risks of resuming fluorouracil in patients with resolved neurologic toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dihydropyrimidine dehydrogenase deficiency: Patients with select homozygous or compound heterozygous mutations of the dihydropyrimidine dehydrogenase (DPD) gene (<i>DPYD</i>) that result in complete or near complete absence of DPD activity are at increased risk for acute early onset of toxicity and severe, life-threatening, or fatal adverse reactions (eg, mucositis, diarrhea, neutropenia, neurotoxicity) due to fluorouracil. Patients with partial DPD activity may also have increased risk of severe, life-threatening, or fatal adverse reactions when administered fluorouracil. Based on clinical assessment of toxicity onset, duration, and severity, withhold or permanently discontinue fluorouracil in patients with evidence of acute early-onset or unusually severe toxicity, which may indicate near complete or total absence of DPD activity. There is no fluorouracil dose that has been proven safe in patients with complete absence of DPD activity and data are insufficient to recommend a specific dose in patients with partial DPD activity as measured by any specific test (according to the prescribing information). The Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group both offer guidance for fluorouracil dosing in patients with known reduced DPD activity (CPIC [Amstutz 2018]; DPWG [Lunenberg 2020]). Consider testing for genetic variants of <i>DPYD </i>prior to fluorouracil initiation to reduce the risk of serious adverse reactions if the patient’s clinical status permits and based on clinical judgement. Serious adverse reactions may still occur even if <i>DPYD </i>variants are not identified.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Warfarin: Clinically significant coagulation parameter elevations have been reported with concomitant use of warfarin and fluorouracil. Closely monitor INR and prothrombin time in patients receiving concomitant coumarin-derivative anticoagulants such as warfarin and adjust the anticoagulant dose accordingly.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration safety issues: Serious errors have occurred when doses administered by continuous ambulatory infusion pumps have inadvertently been given over 1 to 4 hours instead of the intended extended continuous infusion duration. Depending on protocol, infusion duration may range from 46 hours to 7 days for fluorouracil continuous infusions. Ambulatory pumps utilized for continuous infusions should have safeguards to allow for detection of programming errors. If using an elastomeric device for ambulatory continuous infusion, carefully select the device and double check the flow rate. Appropriate prescribing (in single daily doses [not course doses] with instructions to infuse over a specific time period), appropriate training/certification/education of staff involved with dispensing and administration processes, and independent double checks should be utilized throughout dispensing and administration procedures (ISMP [Smetzer 2015]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Antidote: Uridine triacetate has been studied in cases of fluorouracil overdose. In a clinical study of 98 patients who received uridine triacetate for fluorouracil toxicity (due to overdose, accidental capecitabine ingestion, or possible DPD deficiency), 96 patients recovered fully (Bamat 2013). Of 17 patients receiving uridine triacetate beginning within 8 to 96 hours after fluorouracil overdose, all patients fully recovered (von Borstel 2009). Refer to Uridine Triacetate monograph.</p></div>
<div class="block foc drugH1Div" id="F8100923"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg/10 mL (10 mL); 1 g/20 mL (20 mL); 2.5 g/50 mL (50 mL); 5 g/100 mL (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adrucil: 500 mg/10 mL (10 mL [DSC]); 2.5 g/50 mL (50 mL [DSC]); 5 g/100 mL (100 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg/10 mL (10 mL); 1 g/20 mL (20 mL); 2.5 g/50 mL (50 mL); 5 g/100 mL (100 mL)</p></div>
<div class="block geq drugH1Div" id="F8100809"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F8100925"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Fluorouracil Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/20 mL (per mL): $0.33 - $1.43</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 gm/50 mL (per mL): $0.29 - $0.69</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 g/100 mL (per mL): $0.29 - $0.69</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/10 mL (per mL): $0.33 - $1.59</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869165"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/mL (10 mL, 100 mL); 500 mg/10 mL (10 mL); 5 g/100 mL (100 mL)</p></div>
<div class="block admp drugH1Div" id="F52614350"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;">IV: Administration rate varies by protocol; refer to specific reference for protocol. May be administered undiluted by IV push, or further diluted in appropriate fluids and administered by IV bolus, or as a continuous infusion. Avoid extravasation (may be an irritant).</p></div>
<div class="block adm drugH1Div" id="F8100907"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> IV administration rate varies by protocol; refer to specific reference for protocol. May be administered by IV push, IV bolus, or as a continuous infusion. Fluorouracil may be an irritant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449'])">Ref</a></span>); avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">The pharmacy bulk vial is NOT for direct infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">When administering bolus fluorouracil, 30 minutes of cryotherapy is recommended to prevent oral mucositis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32786044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32786044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ophthalmic</b>
<b>(off-label route):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Intraoperative topical application: Aseptically apply fluorouracil-saturated sponges to surgical site of glaucoma filtration surgery for 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26545176','lexi-content-ref-12383808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26545176','lexi-content-ref-12383808'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Postoperative subconjunctival injections were administered 90 to 180 degrees away from the surgical site (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26545176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26545176'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F49132596"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block sts drugH1Div" id="F8100857"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 20°C to 25°C (68°F to 77°F); do not freeze and protect from light. Precipitate formation has been reported if intact vials are stored at lower temperatures but may be redissolved (Cohen 2023); contact manufacturer for current recommendations. Pharmacy bulk vials should be used within 4 hours of initial entry. Syringes and solutions diluted for infusion may be stored for up to 4 hours (at room temperature) prior to administration (according to the manufacturer). Fluorouracil 50 mg/mL in NS was stable in polypropylene infusion pump syringes for 7 days when stored at 30°C (86°F) (Stiles 1996). Stability of fluorouracil 1 mg/mL or 10 mg/mL in NS or D5W in PVC bags was demonstrated for up to 14 days at 4°C (39.2°F) and 21°C (69.8°F) (Martel 1996). Stability of undiluted fluorouracil (50 mg/mL) in ethylene vinyl acetate ambulatory pump reservoirs was demonstrated for 3 days at 4°C (39.2°F) (precipitate formed after 3 days) and for 14 days at 33°C (91.4°F) (Martel 1996). Stability of undiluted fluorouracil (50 mg/mL) in PVC ambulatory pump reservoirs was demonstrated for 5 days at 4°C (39.2°F) (precipitate formed after 5 days) and for 14 days at 33°C (91.4°F) (Martel 1996). Follow USP 797 recommendations for beyond use dates based on the level of risk for preparation.</p></div>
<div class="block usep drugH1Div" id="F53570531"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of carcinoma of stomach (gastric), colon, rectum, breast, and pancreas (FDA approved in adults); has also been used for the treatment of hepatoblastoma, nasopharyngeal carcinoma, head and neck cancer, bladder cancer, and cervical cancer</p></div>
<div class="block mst drugH1Div" id="F8100786"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Fluorouracil may be confused with floxuridine, flucytosine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Continuous infusion:  Serious errors have occurred when doses administered by continuous ambulatory infusion pumps have inadvertently been given over 1 to 4 hours instead of the intended extended continuous infusion duration. Depending on protocol, infusion duration may range from 46 hours to 7 days for fluorouracil continuous infusions. Ambulatory pumps utilized for continuous infusions should have safeguards to allow for detection of programming errors. If using an elastomeric device for ambulatory continuous infusion, carefully select the device and double check the flow rate. Appropriate prescribing (in single daily doses [not course doses] with instructions to infuse over a specific time period), appropriate training/certification/education of staff involved with dispensing and administration processes, and independent double checks should be utilized throughout dispensing and administration procedures.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9844112"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Inhibits</b> CYP2C9 (weak)</p></div>
<div class="block dri drugH1Div" id="F8100851"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Allopurinol: May decrease serum concentrations of the active metabolite(s) of Fluorouracil Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Fluorouracil Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Fluorouracil Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Fluorouracil Products may enhance the myelosuppressive effect of CloZAPine. CloZAPine may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: Fluorouracil Products may enhance the QTc-prolonging effect of Dabrafenib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Fluorouracil Products may enhance the myelosuppressive effect of Fexinidazole. Fexinidazole may enhance the QTc-prolonging effect of Fluorouracil Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: May enhance the QTc-prolonging effect of other Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Folic Acid: May enhance the adverse/toxic effect of Fluorouracil Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: CYP2C9 Inhibitors (Weak) may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemcitabine: May increase the serum concentration of Fluorouracil (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gimeracil: May increase the serum concentration of Fluorouracil Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Interferons (Alfa): May increase the serum concentration of Fluorouracil Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leucovorin Calcium-Levoleucovorin: May enhance the adverse/toxic effect of Fluorouracil Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetroNIDAZOLE (Systemic): May increase the serum concentration of Fluorouracil Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): Fluorouracil Products may enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): Fluorouracil Products may enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">TOLBUTamide: CYP2C9 Inhibitors (Weak) may increase the serum concentration of TOLBUTamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Fluorouracil Products may increase the serum concentration of Vitamin K Antagonists.  Management: Monitor INR and for signs/symptoms of bleeding closely when a fluorouracil product is combined with a vitamin K antagonist (eg, warfarin). Anticoagulant dose adjustment will likely be necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block dic drugH1Div" id="F8100906"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Increase dietary intake of thiamine.</p></div>
<div class="block rep_considerations drugH1Div" id="F53559910"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Patients who could become pregnant and patients with partners who could become pregnant should use effective contraception during treatment and for 3 months following cessation of fluorouracil therapy.</p></div>
<div class="block pri drugH1Div" id="F8100828"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and available human data, fluorouracil may cause fetal harm if administered during pregnancy (NTP 2013). Use in the first trimester is not recommended (Silverstein 2020).</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). In general, if chemotherapy is indicated, it should be avoided during in the first trimester, there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation (ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry or to become a participant, contact Cooper Health (1-877-635-4499).</p></div>
<div class="block mopp drugH1Div" id="F53570533"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential and platelet count, renal function tests, liver function tests; signs of palmar-plantar erythrodysesthesia syndrome, stomatitis, diarrhea, hemorrhage, or gastrointestinal ulcers or bleeding</p></div>
<div class="block pha drugH1Div" id="F8100861"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Fluorouracil is a pyrimidine analog antimetabolite that interferes with DNA and RNA synthesis; after activation, F-UMP (an active metabolite) is incorporated into RNA to replace uracil and inhibit cell growth; the active metabolite F-dUMP, inhibits thymidylate synthetase, depleting thymidine triphosphate (a necessary component of DNA synthesis).</p></div>
<div class="block phk drugH1Div" id="F8100876"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Fluorouracil distributes throughout the body, including brain tissue, CSF, bone marrow, intestinal mucosa, and liver.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; via a dehydrogenase enzyme; FU must be metabolized to form active metabolites, 5-fluoroxyuridine monophosphate (F-UMP) and 5-5-fluoro-2’-deoxyuridine-5’-O-monophosphate (F-dUMP)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Following bolus infusion: 8 to 20 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (5% to 20% as unchanged drug within 6 hours; metabolites over 3 to 4 hours)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961974"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Amgifer | Froben | Strepsils intensive Honey &amp; Lemon</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">5-fluorouracilo Dosa | Ansaid | Cinco-fu | Clinadol | Clinadol Fem | Fada Fluorouracilo | Fluorouracilo | Fluorouracilo filaxis | Fluorouracilo kemex | Fluorouracilo martian | Fluorouracilo rontag | Flurbixim | Oncofu | Tolerane | Triosules</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Fluoro uracil | Fluorouracil accord | Flurbiangin akut | Froben | Ratiodolor flurbiprofen | Strepfen</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Fluorouracil accord | Fluorouracil ebewe</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Fluracedyl | Flurotor | Fluroxan | Urbifen</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Flubilarin | Fluorouracil accord healthcare | Fluorouracil mayne pharma (ben) | Fluorouracil roche | Fluracedyl | Flurbiprofen eg | Fluroblastine | Froben | Strepfen</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Antadys | Flurifen</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">5 fluorouracil ebewe | Fluorouracil | Fluorouracil 5 | Fluorouracil accord | Flurbimed mint | Myprofen | Strepfen | Strepsils Intensive</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Fauldfluor | Fluoro uracil | Fluoruracila | Flusan | Killit | Neugrast | Strepsils</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Angisil x dolo | Fluoro-uracil icn | Fluoro-uracil roche | Fluorouracil accord | Fluorouracil Bigmar | Fluorouracil ebewe | Fluorouracil labatec | Fluorouracil sanofi-synthelabo | Fluorouracil teva | Flurbiangin sandoz | Froben | Neo angin dolo | Strepfen</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Flurifen | Utoral</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Distex | Fluorouracilo | Strepfen</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">An te fan | Fluorouracil co | Fu ke | Fu mi te | Hua kang da</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ansaid | Carebin | Fluoro uracil | Fluorouracilo | Fluroblastin | Megafive | Strepsils Intensive</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">5 fu | Ansaid | Flugalin | Fluoro uracil | Fluorouracil accord | Fluorouracil Hospira | Froben | La fu | Phthoruracil | Strepfen</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">5 Fluoro Uracil | 5 fluorouracil | 5 fu lederle | 5 fu liv pharma | 5 fu Onkovis | 5 fu orca | 5-fu | 5-Fu Medac | 5-fu oncotrade | Benda 5 fu | Bw Flucil | Dobendan direkt flurbiprofen | Dobendan Strepsils Direkt | Fluorosachs | Fluorouracil accord | Fluorouracil amneal | Fluorouracil bhardwaj | Fluorouracil gry | Fluorouracil heumann | Fluorouracil Hexal | Fluorouracil hikma | Fluorouracil phares | Fluorouracil temmler | Fluorouracil tillomed | Fluorouracil vitane | Flurbiangin | Flurbiprofen al | Flurbiprofen dexcel | Froben | Haemato-fu | Neofluor | O fluor | Onkofluor | Ribofluor</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Ansaid | Fivoflu | Fluor-uracil | Fluorouracilo</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">5 Fluoruoracilo | Ansaid | Distex | Fluorouracilo</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">5 fluorouracil | Ansaid | Fluorouracil accord | Froben | Strepsils Intensive</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">5-fluorouracil | Fluoro uracil | Fluorouracil | Froben | Neoflur | Utoral</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Angifen | Fluorouracilo accord | Fluorouracilo Ferrer Farma | Flurbiprofeno sandoz care | Froben | Lizifen | Strefen</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Flourouracil | Kucil</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Fluorouracil accord | Flurablastin | Flusils | Strefen orange</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Antadys | Cebutid | Fluoro uracile | Fluorouracile Accord | Fluorouracile Arrow | Fluorouracile ebewe | Fluorouracile intas | Fluorouracile Mylan | Fluorouracile teva | Fluorouracile Winthrop | Flurbiprofene sandoz | Strefen</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Fluoro uracil | Fluorouracil | Fluorouracil till | Flurbiprofen cox | Flurbiprofen kent | Froben | Strefen | Strefen Honey and Lemon | Streflam | Trav fluorouracil</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">5 fluorouracil Biosyn | 5 fluorouracil ebewe | 5-Fu Medac | Bedice | Bonatol r | Fluoro uracil | Fluorouracil ahcl | Fluorouracil Anabiosis | Fluorouracil ifet | Fluorouracil/ebewe | Fluorouracil/opus | Fluroblastin | Flurofen | Iovic | Neliacan | Pizar | Straben | Strepfen | Uraciflor</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">5-fluorouracil | Fluoro uracil | Fukon | Strepfen</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Fluorouracil Pliva | Fluorouracil sandoz | Strefen | Strepfen</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">5-fluorouracil | Ansaid | Benda 5 fu | Flugalin | Fluoro uracil | Fluorouracil accord | Fluorouracil teva | Phtoruracil</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">5-fluorouracil | Adrucil | Ansaid | Curacil | Fluoro uracil | Fluorouracil | Fluorouracil pfizer | Fluracedyl</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Fluorouracil | Flursil relief | Froben</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">5 flucel | Arflur | Chemoflura | Fivoflu | Florac | Fluorouracil | Fluracil | Froben | Kucil | Oncofluor</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Aspi gola | Fluoro uracile | Fluorouracile | Fluorouracile Accord | Fluorouracile hikma | Fluorouracile hospira | Flurbiprofene eg | Flurbiprofene fg | Formitrol gola | Froben | Frobenactiv | Rofixdol gola | Tantum verdedol</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Fluoro uracil | Maximus</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">5 fu | 5 fu kyowa hakko | Butaparl | Chillos | Fluorouracil | Froben | Fu schering | Lapole | Timadin | Upnon</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Fbi | Fivoflu | Fluracil</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Azotrin | Cebutin | Effcil | Flacil | Fluolex | Flurofen | Froben | Fulfen | Hiropen | Ildong fluorouracil | Jw 5 fu | Mogaften | Pfizer fluorouracil | Ronaben | Soopain | Strepsils | Throkool | Truben | Union fluorouracil | Utoral | Yomogen | Yuraben | Zenstryn</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Fluorouracil ebewe | Froben | Strepsils intensive Honey &amp; Lemon</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Antadys | Fluoro uracil | Fluorouracil | Froben</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">5 fluorouracil | 5-fluorouracil | Ansaid | Benda 5 fu | Flugalin | Fluorouracil | Fluorouracil accord | Fluorouracil Medac | Fluorouracil teva | Phthoruracil</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Fluoro uracil | Flurbiprofen eg | Fluroblastine | Froben | Strepfen</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">5-fluorouracil | Ansaid | Antadys | Flugalin | Fluorouracil | Fluorouracil accord | Fluorouracil ebewe | Froben | Phthoruracil | Strepsils dolointensive | Strepsils Intensive</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Cebutid | Fluoro-Uracile</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acoflut | Ansaid | Ansaid fem | Carebin | Fivoflu | Fluoro uracil | Fluorouracilo | Flurox | Fuoavil | Graneodin f | Ifacil | Tecflu | Ulsacil</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">5 fu | 5-fu | 5-Fu Kyowa | Benda 5 fu | Fluoro uracil | Fluorouracil dbl | Fluracedyl | Strepsils maxpro</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Strepsils Intensive</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Fluorouracil ebewe | Fluracedyl | Froben | Strepfen</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Fluorouracil | Fluorouracil accord | Fluorouracil Hospira | Flurablastin | Strefen</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Fluorouracil | Froben</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ansaid | Fluorouracilo</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Chemoflura | Fivoflu | Fluonco | Fluoro uracil | Fluorouracil | Fluoxan | Fluracedyl | Fluroblastin | Fucil | Racifluoro | Raciwel | Strepsils maxpro | Uflahex | Utoral</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Alivio | Anorcid | Ansaid | Arflur | Arthrofin | Askosaid | Benprofen | Biofen | Biprofin | Brufoz | Dansaid | Digifen | Edge | Endol | Exflam | F-100 | Fabofen | Fbi | Fen | Fenbid | Finn | Flefin | Flourouracil | Flubi | Flugra | Flur | Fluracedyl | Flurant | Flurbid | Flurbin | Flurbizan | Flurfin | Flurgem | Flurip | Fluritab | Flurmov | Flurzo | Flusaid | Fogan | Frobafen | Froben | Frodon | Glofen | Healsed | Inflamatix | Inovan | Iosid | Jasic | Kolzin | Lofrex | Lubifen | Mobez | Naplur | Nefro | Neoflarbi | Novacid | Oncofu | Orthokan | Paincid | Pansaid | Pansol | Pared | Pharmauracil | Prizo | Proben | Q Fur | Rakaprofen | Rasbid | Relaxofen | Relepan | Riboprofen | Robigesic | Rubinol | Rumagesic | Sanid | Santoflur | Saxid | Seco uracil | Stafen | Stanic | Synalgo | Syro | Unesid | Urbicid | Urbofen | Utoral | Velsaid | Vobifen | Zentofen | Zitis</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">5-fluorouracil | 5-fluorouracyl-knoll | Ansaid | Flugalin | Fluorouracil | Fluorouracil accord | Fluorouracil roche | Flurbifex | Polopiryna gardlo | Strepsils dolointensive | Ultravox Maxe</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Adrucil | Ansaid</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cinkef-u | Fluoro uracil | Fluorouracilo | Fluorouracilo accord | Fluorouracilo APS | Fluorouracilo Hikma | Fluorouracilo teva | Flurbiprofeno sandoz | Froben | Macifen | Mentocaina anti-inflam | Reupax</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Clinadol forte | Fluorouracilo fada | Fluorouracilo fapasa | Fluorouracilo fusa | Fluorouracilo libra | Fluorouracilo lkm | Fluorouracilo tuteur | Fluoruracilo imedic | Oncofu | Triosules</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Faringo intensiv | Fluorosindan | Fluorouracil accord | Fluorouracil pch | Septazulen | Strepsils intensiv</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">5-fluorouracil | Fivoflu | Flugalin | Fluorouracil | Fluorouracil deco | Fluorouracil lens | Fluorouracil ronc | Raxtan Sanovel | Strepfen | Strepsils Intensive</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">5 fluorouracil | 5 flurouracil | Fivoflu | Floryl | Fluorouracil | Fluorouracil ebewe | Froben</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fluorouracil accord | Fluorouracil mayne | Fluorouracil teva | Flurablastin | Strefen | Strefen apelsin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Fluorouracil dbl | Fluorouracil pharmachemie | Strepsils maxpro</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">5 fluorouracil | 5 fluorouracil ebewe | 5 fu | Fluoro uracil | Strefen</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ansaid | Flugalin | Fluoro uracil | Fluorouracil 5 fu | Fluorouracil accord | La fu | Strepfen</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">5-fluorouracil | 5-fu | Ansaid | Effcil | Fivoflu | Fluoro uracil | Fluorouracil abic | Fluorouracil dbl | Fluracedyl | Fluracil | Flurox | Flurozin | Id fluorouracil | Strepfen | Strepsils maxpro | Vafu</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">5-fluorouracil | Antadys | Antafen | Cebutid | Cytoflu | Dysfen | Fluorouracile | Flurofen | Prodys</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">5 fluorouracil | 5 frotu | 5 fu | Algopet | Ansaid | Fiera | Fluorouracil kocak | Fluorourcil | Flupen | Flurflex | Fluro 5 | Fortine | Frolix | Majezik | Maxaljin | Maximus | Projezik | Zero P</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Anazin | Anflupin | Ansaid | Baenazin | Biprofen | Butaparl | Efudix | Fluben | Flufen | Flugalin | Fluorouracil | Fluracil | Fluran | Flurozin | Forphen | Froben | Fukon | Furofen | Lefenine | Painil | Stayban | Sulan | Tonlisu</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">5-fluorouracil | 5-fu | Celista for sore throat | Flubrix | Fluorouracil darnitsa | Ftorolek | Ftoruracil | Mazhezik | Strepsils intensiv</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">5-fluorouracil | Biofur | Clinadol | Fluorouracilo filaxis | Fluorouracilo libra | Fluoruracilo | Pentafu</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ansaid | Fivoflu</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Axofinen | Biluracil | Nibelon | Vikaone</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">5 fluorouracil | 5-fluorouracil | Floracor | Fluoro uracil | Fluroblastin | Froben</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">5 flucel | Fluracil | Strepsils Intensive</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Fivoflu | Strepsils Intensive</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Adrucil.1">
<a name="Adrucil.1"></a>Adrucil (fluorouracil injection) bulk [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; February 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Adrucil.2">
<a name="Adrucil.2"></a>Adrucil (fluorouracil injection) [prescribing information]. North Wales, PA: Teva Pharmaceuticals Inc; October 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17664468">
<a name="17664468"></a>Ajani JA, Moiseyenko VM, Tjulandin S, et al. Quality of Life With Docetaxel Plus Cisplatin and Fluorouracil Compared With Cisplatin and Fluorouracil From a Phase III Trial for Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group. <i>J Clin Oncol</i>. 2007;25(22):3210-3216.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/17664468/pubmed" id="17664468" target="_blank">17664468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18430910">
<a name="18430910"></a>Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal Canal: A Randomized Controlled Trial. <i>JAMA</i>. 2008;299(16):1914-1921.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/18430910/pubmed" id="18430910" target="_blank">18430910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18349393">
<a name="18349393"></a>Al-Batran SE, Hartmann JT, Probst S, et al; Arbeitsgemeinschaft Internistische Onkologie. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. <i>J Clin Oncol</i>. 2008;26(9):1435-1442. doi:10.1200/JCO.2007.13.9378<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/18349393/pubmed" id="18349393" target="_blank">18349393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30982686">
<a name="30982686"></a>Al-Batran SE, Homann N, Pauligk C, et al; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. <i>Lancet</i>. 2019;393(10184):1948-1957. doi:10.1016/S0140-6736(18)32557-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/30982686/pubmed" id="30982686" target="_blank">30982686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28784312">
<a name="28784312"></a>Alderson D, Cunningham D, Nankivell M, et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. <i>Lancet Oncol.</i> 2017;18(9):1249-1260. doi:10.1016/S1470-2045(17)30447-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/28784312/pubmed" id="28784312" target="_blank">28784312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30304984">
<a name="30304984"></a>Amagai H, Murakami K, Sakata H, et al. Pharmacokinetics of cisplatin in an esophageal cancer patient on hemodialysis who was treated with a full-dose cisplatin-fluorouracil regimen: a case report. <i>J Oncol Pharm Pract</i>. 2019;25(7):1767-1775. doi:10.1177/1078155218808074<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/30304984/pubmed" id="30304984" target="_blank">30304984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29152729">
<a name="29152729"></a>Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. <i>Clin Pharmacol Ther</i>. 2018;103(2):210-216. doi:10.1002/cpt.911<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/29152729/pubmed" id="29152729" target="_blank">29152729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15175436">
<a name="15175436"></a>André T, Boni C, Mounedji-Boudiaf L, et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. <i>N Engl J Med</i>. 2004;350(23):2343-2351. doi:10.1056/NEJMoa032709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/15175436/pubmed" id="15175436" target="_blank">15175436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10658525">
<a name="10658525"></a>André T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. <i>Eur J Cancer</i>. 1999;35(9):1343-1347.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/10658525/pubmed" id="10658525" target="_blank">10658525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27247216">
<a name="27247216"></a>Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2016;34(22):2654-2668. doi:10.1200/JCO.2016.67.5561<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/27247216/pubmed" id="27247216" target="_blank">27247216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6189661">
<a name="6189661"></a>Balis FM, Holcenberg JS Bleyer WA. Clinical Pharmacokinetics of Commonly Used Anticancer Drugs. <i>Clin Pharmacokinet</i>. 1983;8(3):202-232.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/6189661/pubmed" id="6189661" target="_blank">6189661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bamat.1">
<a name="Bamat.1"></a>Bamat MK, Tremmel R, von Borstel R, et al. Clinical experience with uridine triacetate for 5-FU overexposure: an update [abstract e20592 from 2013 ASCO Annual Meeting]. <i>J Clin Oncol</i>. 2013;31(18s):e20592.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20728210">
<a name="20728210"></a>Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. <i>Lancet</i>. 2010;376(9742):687-697.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/20728210/pubmed" id="20728210" target="_blank">20728210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22261362">
<a name="22261362"></a>Bourhis J, Sire C, Graff P, et al. Concomitant Chemoradiotherapy versus Acceleration of Radiotherapy With or Without Concomitant Chemotherapy in Locally Advanced Head and Neck Carcinoma (GORTEC 99-02): An Open-Label Phase 3 Randomised Trial. <i>Lancet Oncol</i>. 2012;13(2):145-153.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/22261362/pubmed" id="22261362" target="_blank">22261362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22359313">
<a name="22359313"></a>Buehrlen M, Zwaan CM, Granzen B, et al. Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG. <i>Cancer</i>. 2012;118(19):4892-4900.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/22359313/pubmed" id="22359313" target="_blank">22359313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31679945">
<a name="31679945"></a>Burtness B, Harrington KJ, Greil R, et al; KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet</i>. 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/31679945/pubmed" id="31679945" target="_blank">31679945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2705401">
<a name="2705401"></a>Buzdar AU, Kau SW, Smith TL, et al. Ten-Year Results of FAC Adjuvant Chemotherapy Trial in Breast Cancer. <i>Am J Clin Oncol</i>. 1989;12(2):123-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/2705401/pubmed" id="2705401" target="_blank">2705401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26545176">
<a name="26545176"></a>Cabourne E, Clarke JC, Schlottmann PG, Evans JR. Mitomycin C versus 5-Fluorouracil for wound healing in glaucoma surgery. <i>Cochrane Database Syst Rev</i>. 2015;(11):CD006259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/26545176/pubmed" id="26545176" target="_blank">26545176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21918965">
<a name="21918965"></a>Casanova M, Bisogno G, Gandola L, et al. A prospective protocol for nasopharyngeal carcinoma in children and adolescents: the Italian Rare Tumors in Pediatric Age (TREP) project. <i>Cancer</i>. 2012;118(10):2718-2725.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/21918965/pubmed" id="21918965" target="_blank">21918965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18421053">
<a name="18421053"></a>Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. <i>J Clin Oncol</i>. 2008;26(12):2006-2012. doi:10.1200/JCO.2007.14.9898<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/18421053/pubmed" id="18421053" target="_blank">18421053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28456635">
<a name="28456635"></a>Chang SS, Bochner BH, Chou R, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. <i>J Urol</i>. 2017;198(3):552-559. doi:10.1016/j.juro.2017.04.086<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/28456635/pubmed" id="28456635" target="_blank">28456635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12177775">
<a name="12177775"></a>Cheeseman SL, Joel SP, Chester JD, et al. A Modified de Gramont’ Regimen of Fluorouracil, Alone and With Oxaliplatin, for Advanced Colorectal Cancer. <i>Br J Cancer</i>. 2002;87(4):393-399.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/12177775/pubmed" id="12177775" target="_blank">12177775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cohen.1">
<a name="Cohen.1"></a>Cohen M, Bertagnoli S, Shastay A, Shultz K, eds. Proper deployment of REMS to reduce potential drug-related harm and medication errors — part I. <i>ISMP Medication Safety Alert! Acute Care Edition</i>. 2023;28(14):1-3.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22375089">
<a name="22375089"></a>Connolly S, Scott P, Cochrane D, Harte R. A case report of 5-fluorouracil-induced coronary artery vasospasm. <i>Ulster Med J</i>. 2010;79(3):135-136.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/22375089/pubmed" id="22375089" target="_blank">22375089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21561347">
<a name="21561347"></a>Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. <i>N Engl J Med.</i> 2011;364(19):1817-1825. doi:10.1056/NEJMoa1011923<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/21561347/pubmed" id="21561347" target="_blank">21561347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575490">
<a name="30575490"></a>Conroy T, Hammel P, Hebbar M, et al; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. <i>N Engl J Med.</i> 2018;379(25):2395-2406. doi:10.1056/NEJMoa1809775<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/30575490/pubmed" id="30575490" target="_blank">30575490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20940718">
<a name="20940718"></a>Conroy T, Yataghène Y, Etienne PL, et al. Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. <i>Br J Cancer</i>. 2010;103(9):1349-1355.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/20940718/pubmed" id="20940718" target="_blank">20940718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26338525">
<a name="26338525"></a>Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. <i>Lancet Oncol</i>. 2015;16(13):1306-1315. doi:10.1016/S1470-2045(15)00122-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/26338525/pubmed" id="26338525" target="_blank">26338525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10944126">
<a name="10944126"></a>De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. <i>J Clin Oncol.</i> 2000;18(16):2938-2947.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/10944126/pubmed" id="10944126" target="_blank">10944126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14657228">
<a name="14657228"></a>Denis F, Garaud P, Bardet E, et al. Final Results of the 94-01 French Head and Neck Oncology and Radiotherapy Group Randomized Trial Comparing Radiotherapy Alone With Concomitant Radiochemotherapy in Advanced-Stage Oropharynx Carcinoma. <i>J Clin Oncol</i>. 2004;22(1):69-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/14657228/pubmed" id="14657228" target="_blank">14657228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22958571">
<a name="22958571"></a>Di Lorenzo G, Buonerba C, Federico P, et al. Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. <i>BJU Int</i>. 2012;110(11, pt B):E661-E666.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/22958571/pubmed" id="22958571" target="_blank">22958571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10971206">
<a name="10971206"></a>Diasio RB, Johnson MR. The Role of Pharmacogenetics and Pharmacogenomics in Cancer Chemotherapy With 5-Fluorouracil. <i>Pharmacology</i>. 2000;61(3):199-203.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/10971206/pubmed" id="10971206" target="_blank">10971206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35108470">
<a name="35108470"></a>Doki Y, Ajani JA, Kato K, et al; CheckMate 648 Trial Investigators. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. <i>N Engl J Med</i>. 2022;386(5):449-462. doi:10.1056/NEJMoa2111380<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/35108470/pubmed" id="35108470" target="_blank">35108470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8380296">
<a name="8380296"></a>Douglass EC, Reynolds M, Finegold M, Cantor AB, Glicksman A. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. <i>J Clin Oncol</i>. 1993;11(1):96-99.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/8380296/pubmed" id="8380296" target="_blank">8380296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24718886">
<a name="24718886"></a>Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. <i>Ann Oncol</i>. 2014;25(7):1346-1355. doi:10.1093/annonc/mdu141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/24718886/pubmed" id="24718886" target="_blank">24718886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20921465">
<a name="20921465"></a>Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. <i>J Clin Oncol</i>. 2010;28(31):4697-4705. doi:10.1200/JCO.2009.27.4860<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/20921465/pubmed" id="20921465" target="_blank">20921465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11169943">
<a name="11169943"></a>Dowell JE, Garrett AM, Shyr Y, et al. A Randomized Phase II Trial in Patients With Carcinoma of an Unknown Primary Site. <i>Cancer</i>. 2001;91(3):592-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/11169943/pubmed" id="11169943" target="_blank">11169943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26687170">
<a name="26687170"></a>Eads JR, Beumer JH, Negrea L, Holleran JL, Strychor S, Meropol NJ. A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis. <i>Cancer Chemother Pharmacol</i>. 2016;77(2):333-338. doi:10.1007/s00280-015-2939-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/26687170/pubmed" id="26687170" target="_blank">26687170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23047592">
<a name="23047592"></a>Earl HM, Hiller L, Dunn JA, et al; NEAT Investigators and the SCTBG. Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. <i>Br J Cancer</i>. 2012;107(8):1257-1267. doi:10.1038/bjc.2012.370<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/23047592/pubmed" id="23047592" target="_blank">23047592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14990643">
<a name="14990643"></a>Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of Radiation Therapy Oncology Group Trial (RTOG) 90-01. <i>J Clin Oncol</i>. 2004;22(5):872-880.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/14990643/pubmed" id="14990643" target="_blank">14990643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32786044">
<a name="32786044"></a>Elad S, Cheng KKF, Lalla RV, et al; Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i>. 2020;126(19):4423-4431. doi:10.1002/cncr.33100<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/32786044/pubmed" id="32786044" target="_blank">32786044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25373735">
<a name="25373735"></a>Eng C, Chang GJ, You YN, et al. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. <i>Oncotarget</i>. 2014;5(22):11133-11142. doi:10.18632/oncotarget.2563<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/25373735/pubmed" id="25373735" target="_blank">25373735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27382098">
<a name="27382098"></a>Enzinger PC, Burtness BA, Niedzwiecki D, et al. CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. <i>J Clin Oncol.</i> 2016;34(23):2736-2742. doi:10.1200/JCO.2015.65.5092<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/27382098/pubmed" id="27382098" target="_blank">27382098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Kenar D. Jhaveri, MD; Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27251602">
<a name="27251602"></a>Fakhri Y, Dalsgaard M, Nielsen D, Lav Madsen P. 5-Fluorouracil-induced acute reversible heart failure not explained by coronary spasms, myocarditis or takotsubo: lessons from MRI. <i>BMJ Case Rep</i>. 2016;2016:bcr2015213783. doi:10.1136/bcr-2015-213783<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/27251602/pubmed" id="27251602" target="_blank">27251602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17470860">
<a name="17470860"></a>Falcone A, Ricci S, Brunetti I, et al; Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. <i>J Clin Oncol</i>. 2007;25(13):1670-1676. doi: 10.1200/JCO.2006.09.0928.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/17470860/pubmed" id="17470860" target="_blank">17470860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8823332">
<a name="8823332"></a>Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. <i>J Clin Oncol.</i> 1996;14(9):2527-2539.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/8823332/pubmed" id="8823332" target="_blank">8823332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12853359">
<a name="12853359"></a>Fleming GF, Schilsky RL, Schumm LP, et al. Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. <i>Ann Oncol</i>. 2003;14(7):1142-1147. doi:10.1093/annonc/mdg302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/12853359/pubmed" id="12853359" target="_blank">12853359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Biolyse.1">
<a name="Biolyse.1"></a>Fluorouracil injection [product monograph]. St. Catharines, Ontario, Canada: Biolyse Pharma Corp; March 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xiromed.1">
<a name="Xiromed.1"></a>Fluorouracil injection 0.5 g and 1 g [prescribing information]. Florham Park, NJ: Xiromed; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xiromed.1">
<a name="Xiromed.1"></a>Fluorouracil injection 2.5 g and 5 g [prescribing information]. Florham Park, NJ: Xiromed; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16473644">
<a name="16473644"></a>Floyd J, Mirza I, Sachs B, et al. Hepatotoxicity of chemotherapy. <i>Semin Oncol</i>. 2006;33(1):50-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/16473644/pubmed" id="16473644" target="_blank">16473644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1634913">
<a name="1634913"></a>Forastiere AA, Metch B, Schuller DE, et al. Randomized Comparison of Cisplatin Plus Fluorouracil and Carboplatin Plus Fluorouracil Versus Methotrexate in Advanced Squamous-Cell Carcinoma of the Head and Neck: A Southwest Oncology Group Study. <i>J Clin Oncol</i>. 1992;10(8):1245-1251.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/1634913/pubmed" id="1634913" target="_blank">1634913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24082383">
<a name="24082383"></a>Fradley MG, Barrett CD, Clark JR, Francis SA. Ventricular fibrillation cardiac arrest due to 5-fluorouracil cardiotoxicity. <i>Tex Heart Inst J</i>. 2013;40(4):472-476.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/24082383/pubmed" id="24082383" target="_blank">24082383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17947725">
<a name="17947725"></a>Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. <i>J Clin Oncol</i>. 2007;25(30):4779-4786. doi:10.1200/JCO.2007.11.3357<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/17947725/pubmed" id="17947725" target="_blank">17947725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29531838">
<a name="29531838"></a>Funakoshi T, Horimatsu T, Nakamura M, et al. Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan. <i>ESMO Open</i>. 2018;3(2):e000301. doi:10.1136/esmoopen-2017-000301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/29531838/pubmed" id="29531838" target="_blank">29531838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22153890">
<a name="22153890"></a>Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (Neosphere): a randomised multicentre, open-label, phase 2 trial. <i>Lancet Oncol</i>. 2012;13(1):25-32. doi:10.1016/S1470-2045(11)70336-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/22153890/pubmed" id="22153890" target="_blank">22153890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15908667">
<a name="15908667"></a>Gibson MK, Li Y, Murphy B, et al. Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group. <i>J Clin Oncol</i>. 2005;23(15):3562-3567.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/15908667/pubmed" id="15908667" target="_blank">15908667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9653488">
<a name="9653488"></a>Goldhirsch A, Colleoni M, Coates AS, et al. Adding Adjuvant CMF Chemotherapy to Either Radiotherapy or Tamoxifen: Are All CMFs Alike? The International Breast Cancer Study Group (IBCSG). <i>Ann Oncol</i>. 1998;9(5):489-493.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/9653488/pubmed" id="9653488" target="_blank">9653488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24554410">
<a name="24554410"></a>Green E, Wilkins M, Bunce C, Wormald R. 5-Fluorouracil for glaucoma surgery. <i>Cochrane Database Syst Rev</i>. 2014;(2):CD001132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/24554410/pubmed" id="24554410" target="_blank">24554410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29590544">
<a name="29590544"></a>Grothey A, Sobrero AF, Shields AF, et al. Duration of adjuvant chemotherapy for stage III colon cancer. <i>N Engl J Med</i>. 2018;378(13):1177-1188. doi:10.1056/NEJMoa1713709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/29590544/pubmed" id="29590544" target="_blank">29590544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23150707">
<a name="23150707"></a>Gunderson LL, Winter KA, Ajani JA, et al. Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin versus Fluorouracil/Cisplatin. <i>J Clin Oncol</i>. 2012;30(35):4344-4351.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/23150707/pubmed" id="23150707" target="_blank">23150707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16314627">
<a name="16314627"></a>Haller DG, Catalano PJ, Macdonald JS, et al. Phase III Study of Fluorouracil, Leucovorin, and Levamisole in High-Risk Stage II and III Colon Cancer: Final Report of Intergroup 0089. <i>J Clin Oncol</i>. 2005;23(34):8671-8678.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/16314627/pubmed" id="16314627" target="_blank">16314627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36882809">
<a name="36882809"></a>Hemachudha P, Rattanawong W, Pongpitakmetha T, Phuenpathom W. Fluorouracil-induced leukoencephalopathy mimicking neuroleptic malignant syndrome: a case report. <i>J Med Case Rep</i>. 2023;17(1):86. doi:10.1186/s13256-023-03814-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/36882809/pubmed" id="36882809" target="_blank">36882809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18448556">
<a name="18448556"></a>Hezel AF, Zhu AX. Systemic Therapy for Biliary Tract Cancers. <i>Oncologist</i>. 2008;13(4):415-423.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/18448556/pubmed" id="18448556" target="_blank">18448556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16275937">
<a name="16275937"></a>Hitt R, López-Pousa A, Martínez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. <i>J Clin Oncol</i>. 2005;23(34):8636-8645.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/16275937/pubmed" id="16275937" target="_blank">16275937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24608198">
<a name="24608198"></a>Hochster HS, Grothey A, Hart L, et al. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. <i>Ann Oncol.</i> 2014;25(6):1172-1178. doi:10.1093/annonc/mdu107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/24608198/pubmed" id="24608198" target="_blank">24608198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28536826">
<a name="28536826"></a>Horimatsu T, Nakayama N, Moriwaki T, et al. A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma. <i>Int J Clin Oncol</i>. 2017;22(5):905-912. doi:10.1007/s10147-017-1138-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/28536826/pubmed" id="28536826" target="_blank">28536826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22512481">
<a name="22512481"></a>James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. <i>N Engl J Med.</i> 2012;366(16):1477-1488.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/22512481/pubmed" id="22512481" target="_blank">22512481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34912120">
<a name="34912120"></a>Janjigian YY, Kawazoe A, Yanez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. <i>Nature.</i> 2021a;600(7890):727-730.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/34912120/pubmed" id="34912120" target="_blank">34912120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34102137">
<a name="34102137"></a>Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. <i>Lancet</i>. 2021b;398(10294):27-40. doi:10.1016/S0140-6736(21)00797-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/34102137/pubmed" id="34102137" target="_blank">34102137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20118214">
<a name="20118214"></a>Janus N, Thariat J, Boulanger H, et al. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. <i>Ann Oncol</i>. 2010;21(7):1395-1403.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/20118214/pubmed" id="20118214" target="_blank">20118214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32516007">
<a name="32516007"></a>Johnson HM, Mitchell KB; Academy of Breastfeeding Medicine. ABM clinical protocol #34: breast cancer and breastfeeding. <i>Breastfeed Med</i>. 2020;15(7):429-434. doi:10.1089/bfm.2020.29157.hmj<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/32516007/pubmed" id="32516007" target="_blank">32516007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31180816">
<a name="31180816"></a>Khorana AA, McKernin SE, Berlin J, et al. Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update. <i>J Clin Oncol</i>. 2019;37(23):2082-2088. doi:10.1200/JCO.19.00946<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/31180816/pubmed" id="31180816" target="_blank">31180816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22701028">
<a name="22701028"></a>Killu A, Madhavan M, Prasad K, Prasad A. 5-fluorouracil induced pericarditis. <i>BMJ Case Rep</i>. 2011;2011:bcr0220113883. doi:10.1136/bcr.02.2011.3883<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/22701028/pubmed" id="22701028" target="_blank">22701028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17963825">
<a name="17963825"></a>Kim YS, Shin SS, Nam JH, et al. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer. <i>Gynecol Oncol.</i> 2008;108(1):195-200. doi:10.1016/j.ygyno.2007.09.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/17963825/pubmed" id="17963825" target="_blank">17963825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kitai.1">
<a name="Kitai.1"></a>Kitai Y, Matsubara T, Funakoshi T, Horimatsu T, Muto M, Yanagita M. Cancer screening and treatment in patients with end-stage renal disease: remaining issues in the field of onco-nephrology. <i>Ren Replace Ther</i>. 2016;2:33. doi:10.1186/s41100-016-0046-y</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15570077">
<a name="15570077"></a>Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas. <i>J Clin Oncol</i>. 2004;22(23):4762-4771.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/15570077/pubmed" id="15570077" target="_blank">15570077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17470851">
<a name="17470851"></a>Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin as Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07. <i>J Clin Oncol</i>. 2007;25(16):2198-2204.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/17470851/pubmed" id="17470851" target="_blank">17470851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17848753">
<a name="17848753"></a>Kusaba H, Shibata Y, Arita S, et al. Infusional 5-Fluorouracil and Cisplatin as First-Line Chemotherapy in Patients With Carcinoma of Unknown Primary Site. <i>Med Oncol</i>. 2007;24(2):259-264.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/17848753/pubmed" id="17848753" target="_blank">17848753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33798493">
<a name="33798493"></a>Lamarca A, Palmer DH, Wasan HS, et al; Advanced Biliary Cancer Working Group. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. <i>Lancet Oncol.</i> 2021;22(5):690-701. doi:10.1016/S1470-2045(21)00027-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/33798493/pubmed" id="33798493" target="_blank">33798493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8641609">
<a name="8641609"></a>Landoni F, Maneo A, Zanetta G, et al. Concurrent preoperative chemotherapy with 5-fluorouracil and mitomycin C and radiotherapy (FUMIR) followed by limited surgery in locally advanced and recurrent vulvar carcinoma. <i>Gynecol Oncol</i>. 1996;61(3):321-327.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/8641609/pubmed" id="8641609" target="_blank">8641609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9704715">
<a name="9704715"></a>Levine MN, Bramwell VH, Pritchard KI, et al. Randomized Trial of Intensive Cyclophosphamide, Epirubicin, and Fluorouracil Chemotherapy Compared With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer, National Cancer Institute of Canada Clinical Trials Group. <i>J Clin Oncol</i>. 1998;16(8):2651-2658.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/9704715/pubmed" id="9704715" target="_blank">9704715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30986117">
<a name="30986117"></a>Lieu C, Kennedy EB, Bergsland E, et al. Duration of oxaliplatin-containing adjuvant therapy for stage III colon cancer: ASCO clinical practice guideline. <i>J Clin Oncol</i>. 2019;37(16):1436-1447. doi:10.1200/JCO.19.00281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/30986117/pubmed" id="30986117" target="_blank">30986117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25337750">
<a name="25337750"></a>Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. <i>N Engl J Med</i>. 2014;371(17):1609-1618. doi:10.1056/NEJMoa1403108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/25337750/pubmed" id="25337750" target="_blank">25337750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31745289">
<a name="31745289"></a>Lunenburg CATC, van der Wouden CH, Nijenhuis M, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. <i>Eur J Hum Genet</i>. 2020;28(4):508-517. doi:10.1038/s41431-019-0540-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/31745289/pubmed" id="31745289" target="_blank">31745289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J</i>. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8729637">
<a name="8729637"></a>Martel P, Petit I, Pinguet F, et al. Long-term stability of 5-fluorouracil stored in PVC bags and in ambulatory pump reservoirs. <i>J Pharm Biomed Anal</i>. 1996;14(4):395-399.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/8729637/pubmed" id="8729637" target="_blank">8729637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32335061">
<a name="32335061"></a>McComas K, Agarwal N, Bowen G, et al. Definitive chemoradiotherapy for locally advanced, lymph-node positive, nonmetastatic penile squamous cell carcinoma. <i>Clin Genitourin Cancer.</i> 2020;18(5):e573-e584. doi:10.1016/j.clgc.2020.02.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/32335061/pubmed" id="32335061" target="_blank">32335061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11734065">
<a name="11734065"></a>McGlinchey PG, Webb ST, Campbell NP. 5-fluorouracil-induced cardiotoxicity mimicking myocardial infarction: a case report. <i>BMC Cardiovasc Disord</i>. 2001;1:3. doi:10.1186/1471-2261-1-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/11734065/pubmed" id="11734065" target="_blank">11734065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15999363">
<a name="15999363"></a>Mertens R, Granzen B, Lassay L, et al. Treatment of nasopharyngeal carcinoma in children and adolescents: definitive results of a multicenter study (NPC-91-GPOH). <i>Cancer</i>. 2005;104(5):1083-1089.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/15999363/pubmed" id="15999363" target="_blank">15999363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11870157">
<a name="11870157"></a>Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. <i>J Clin Oncol.</i> 2002;20(5):1167-1174. doi:10.1200/JCO.2002.20.5.1167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/11870157/pubmed" id="11870157" target="_blank">11870157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31609637">
<a name="31609637"></a>Modest DP, Martens UM, Riera-Knorrenschild J, et al. FOLFOXIRI plus panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer: the randomized, open-label, phase II VOLFI study (AIO KRK0109). <i>J Clin Oncol.</i> 2019;37(35):3401-3411. doi:10.1200/JCO.19.01340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/31609637/pubmed" id="31609637" target="_blank">31609637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30316684">
<a name="30316684"></a>Mondaca S, Chatila WK, Bates D, et al. FOLFCIS treatment and genomic correlates of response in advanced anal squamous cell cancer. <i>Clin Colorectal Cancer.</i> 2019;18(1):e39-e52. doi:10.1016/j.clcc.2018.09.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/30316684/pubmed" id="30316684" target="_blank">30316684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9747823">
<a name="9747823"></a>Moore DH, Thomas GM, Montana GS, Saxer A, Gallup DG, Olt G. Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. <i>Int J Radiat Oncol Biol Phys</i>. 1998;42(1):79-85. doi:10.1016/s0360-3016(98)00193-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/9747823/pubmed" id="9747823" target="_blank">9747823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21276754">
<a name="21276754"></a>Morgan C, Tillett T, Braybrooke J, et al. Management of Uncommon Chemotherapy-Induced Emergencies. <i>Lancet Oncol</i>. 2011;12(8):806-814.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/21276754/pubmed" id="21276754" target="_blank">21276754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10202164">
<a name="10202164"></a>Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. <i>N Engl J Med</i>. 1999;340(15):1137-1143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/10202164/pubmed" id="10202164" target="_blank">10202164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24736875">
<a name="24736875"></a>National Toxicology Program. NTP monograph: developmental effects and pregnancy outcomes associated with cancer chemotherapy use during pregnancy. <i>NTP Monogr</i>. 2013;(2):i-214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/24736875/pubmed" id="24736875" target="_blank">24736875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28204913">
<a name="28204913"></a>Nishikawa Y, Funakoshi T, Horimatsu T, et al. Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. <i>Cancer Chemother Pharmacol</i>. 2017;79(3):629-633. doi:10.1007/s00280-017-3249-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/28204913/pubmed" id="28204913" target="_blank">28204913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24799484">
<a name="24799484"></a>O’Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. <i>J Clin Oncol.</i> 2014;32(18):1927-1934. doi:10.1200/JCO.2013.53.7753<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/24799484/pubmed" id="24799484" target="_blank">24799484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35914638">
<a name="35914638"></a>Obermannová R, Alsina M, Cervantes A, et al; ESMO Guidelines Committee. Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. <i>Ann Oncol.</i> 2022;33(10):992-1004. doi:10.1016/j.annonc.2022.07.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/35914638/pubmed" id="35914638" target="_blank">35914638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24982456">
<a name="24982456"></a>Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. <i>J Clin Oncol</i>. 2014;32(23):2423-2429. doi:10.1200/JCO.2013.53.6995<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/24982456/pubmed" id="24982456" target="_blank">24982456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10894865">
<a name="10894865"></a>Ortega JA, Douglass EC, Feusner JH, et al. Randomized Comparison of Cisplatin/Vincristine/Fluorouracil and Cisplatin/Continuous Infusion Doxorubicin for Treatment of Pediatric Hepatoblastoma: A Report From the Children's Cancer Group and the Pediatric Oncology Group. <i>J Clin Oncol.</i> 2000;18(14):2665-2675.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/10894865/pubmed" id="10894865" target="_blank">10894865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33011861">
<a name="33011861"></a>Ozaki Y, Imamaki H, Ikeda A, et al. Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses. <i>Cancer Chemother Pharmacol</i>. 2020;86(5):693-699. doi:10.1007/s00280-020-04158-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/33011861/pubmed" id="33011861" target="_blank">33011861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18930550">
<a name="18930550"></a>Palanca-Capistrano AM, Hall J, Cantor LB, Morgan L, Hoop J, WuDunn D. Long-term outcomes of intraoperative 5-fluorouracil versus intraoperative mitomycin C in primary trabeculectomy surgery. <i>Ophthalmology</i>. 2009;116(2):185-190.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/18930550/pubmed" id="18930550" target="_blank">18930550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-vi170. doi:10.1093/annonc/mdt199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20921462">
<a name="20921462"></a>Peeters M, Price TJ, Cervantes A, et al. Randomized phase iii study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. <i>J Clin Oncol</i>. 2010; 28(31):4706-4713. doi:10.1200/JCO.2009.27.6055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/20921462/pubmed" id="20921462" target="_blank">20921462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21565490">
<a name="21565490"></a>Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. <i>Eur J Cancer.</i> 2011;47(11):1676-1681.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/21565490/pubmed" id="21565490" target="_blank">21565490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22997449">
<a name="22997449"></a>Pérez Fidalgo JA, García Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F; ESMO Guidelines Working Group. Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines. <i>Ann Oncol</i>. 2012;23(suppl 7):vii167-173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/22997449/pubmed" id="22997449" target="_blank">22997449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19318632">
<a name="19318632"></a>Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. <i>J Natl Cancer Inst</i>. 2009;101(7):498-506. doi:10.1093/jnci/djp007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/19318632/pubmed" id="19318632" target="_blank">19318632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17960013">
<a name="17960013"></a>Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and Fluorouracil Alone or With Docetaxel in Head and Neck Cancer.<i> N Engl J Med</i>. 2007;357(17):1705-1715.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/17960013/pubmed" id="17960013" target="_blank">17960013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-630214">
<a name="630214"></a>Pottage A, Holt S, Ludgate S, Langlands AO. Fluorouracil cardiotoxicity. <i>Br Med J</i>. 1978;1(6112):547. doi:10.1136/bmj.1.6112.547<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/630214/pubmed" id="630214" target="_blank">630214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18319412">
<a name="18319412"></a>Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma: A Randomized Controlled Trial. <i>JAMA.</i> 2008;299(9):1019-1026.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/18319412/pubmed" id="18319412" target="_blank">18319412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11840401">
<a name="11840401"></a>Rengelshausen J, Hull WE, Schwenger V, Göggelmann C, Walter-Sack I, Bommer J. Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis. <i>Am J Kidney Dis</i>. 2002;39(2):E10. doi:10.1053/ajkd.2002.30584<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/11840401/pubmed" id="11840401" target="_blank">11840401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15641027">
<a name="15641027"></a>Rodriguez-Galindo C, Wofford M, Castleberry RP, et al. Preradiation chemotherapy with methotrexate, cisplatin, 5-fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma. <i>Cancer.</i> 2005;103(4):850-857.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/15641027/pubmed" id="15641027" target="_blank">15641027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23704196">
<a name="23704196"></a>Schneeweiss A, Chia, S, Hickish, T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). <i>Ann Oncol</i>. 2013;24(9):2278-2284. doi:10.1093/annonc/mdt182<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/23704196/pubmed" id="23704196" target="_blank">23704196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26438119">
<a name="26438119"></a>Shah MA, Janjigian YY, Stoller R, et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. <i>J Clin Oncol</i>. 2015;33(33):3874-3879. doi:10.1200/JCO.2015.60.7465<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/26438119/pubmed" id="26438119" target="_blank">26438119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32568633">
<a name="32568633"></a>Shah MA, Kennedy EB, Catenacci DV, et al. Treatment of locally advanced esophageal carcinoma: ASCO guideline. <i>J Clin Oncol</i>. 2020;38(23):2677-2694. doi:10.1200/JCO.20.00866<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/32568633/pubmed" id="32568633" target="_blank">32568633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32910882">
<a name="32910882"></a>Silverstein J, Post AL, Chien AJ, et al. Multidisciplinary management of cancer during pregnancy. <i>JCO Oncol Pract</i>. 2020;16(9):545-557. doi:10.1200/OP.20.00077<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/32910882/pubmed" id="32910882" target="_blank">32910882</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Smetzer J, Cohen M, eds. Accidental overdoses involving fluorouracil infusions. <i>ISMP Medication Safety Alert! Acute Care Edition</i>. 2015;20(12):1-6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32861308">
<a name="32861308"></a>Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. <i>Lancet</i>. 2020;396(10251):635-648. doi:10.1016/S0140-6736(20)31288-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/32861308/pubmed" id="32861308" target="_blank">32861308</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. <i>J Clin Oncol</i>. Published online August 5, 2020. doi:10.1200/JCO.20.01364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/32755482/pubmed" id="32755482" target="_blank">32755482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-38088292">
<a name="38088292"></a>Steen SW, Sørbye H, Jazbani M, Garresori H. Takotsubo syndrome during treatment with 5-fluorouracil. <i>Tidsskr Nor Laegeforen</i>. 2023;143(18):10.4045/tidsskr.23.0338. doi:10.4045/tidsskr.23.0338<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/38088292/pubmed" id="38088292" target="_blank">38088292</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23241239">
<a name="23241239"></a>Steger F, Hautmann MG, Kölbl O. 5-FU-induced cardiac toxicity--an underestimated problem in radiooncology?. <i>Radiat Oncol</i>. 2012;7:212. doi:10.1186/1748-717X-7-212<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/23241239/pubmed" id="23241239" target="_blank">23241239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8809281">
<a name="8809281"></a>Stiles ML, Allen LV, and Prince SJ. Stability of deferoxamine mesylate, floxuridine, fluorouracil, hydromorphone hydrochloride, lorazepam, and midazolam hydrochloride in polypropylene infusion-pump syringes. <i>Am J Health Syst Pharm</i>. 1996;53(13):1583-1588.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/8809281/pubmed" id="8809281" target="_blank">8809281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34454674">
<a name="34454674"></a>Sun JM, Shen L, Shah MA, et al; KEYNOTE-590 Investigators. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. <i>Lancet</i>. 2021;398(10302):759-771. doi:10.1016/S0140-6736(21)01234-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/34454674/pubmed" id="34454674" target="_blank">34454674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26899755">
<a name="26899755"></a>Syed Q, Hendler KT, Koncilja K. The impact of aging and medical status on dysgeusia. <i>Am J Med</i>. 2016;129(7):753.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/26899755/pubmed" id="26899755" target="_blank">26899755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25877855">
<a name="25877855"></a>Tabernero J, Yoshino T, Cohn AL, et al; RAISE Study Investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. <i>Lancet Oncol</i>. 2015;16(5):499-508. doi:10.1016/S1470-2045(15)70127-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/25877855/pubmed" id="25877855" target="_blank">25877855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18309943">
<a name="18309943"></a>Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. <i>J Clin Oncol</i>. 2008;26(7):1086-1092.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/18309943/pubmed" id="18309943" target="_blank">18309943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19339720">
<a name="19339720"></a>Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. <i>N Engl J Med</i>. 2009;360(14):1408-1417. doi:10.1056/NEJMoa0805019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/19339720/pubmed" id="19339720" target="_blank">19339720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21502544">
<a name="21502544"></a>Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.<i> J Clin Oncol</i>. 2011;29(15):2011-2019. doi:10.1200/JCO.2010.33.5091<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/21502544/pubmed" id="21502544" target="_blank">21502544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17075117">
<a name="17075117"></a>Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group. <i>J Clin Oncol</i>. 2006;24(31):4991-4997.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/17075117/pubmed" id="17075117" target="_blank">17075117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22949147">
<a name="22949147"></a>Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. <i>J Clin Oncol.</i> 2012;30(28):3499-3506. doi:10.1200/JCO.2012.42.8201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/22949147/pubmed" id="22949147" target="_blank">22949147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28632865">
<a name="28632865"></a>Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. <i>JAMA</i>. 2017;317(23):2392-2401. doi:10.1001/jama.2017.7105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/28632865/pubmed" id="28632865" target="_blank">28632865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18784101">
<a name="18784101"></a>Vermorken JB, Mesia R, Rivera F, et al. Platinum-Based Chemotherapy Plus Cetuximab in Head and Neck Cancer. <i>N Engl J Med</i>. 2008;359(11):1116-1127.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/18784101/pubmed" id="18784101" target="_blank">18784101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17960012">
<a name="17960012"></a>Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer.<i> N Engl J Med</i>. 2007;357(17):1695-1704.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/17960012/pubmed" id="17960012" target="_blank">17960012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-vonBorstel.1">
<a name="vonBorstel.1"></a>von Borstel R, O’Neil J, Bamat M. Vistonuridine: an orally administered, life-saving antidote for 5-fluorouracil (5FU) overdose. <i>J Clin Oncol</i>. 2009;27(15S):9616 [abstract 9616 from 2009 ASCO Annual Meeting].</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26615328">
<a name="26615328"></a>Wang-Gillam A, Li CP, Bodoky G, et al; NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. <i>Lancet</i>. 2016;387(10018):545-557. doi:10.1016/S0140-6736(15)00986-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/26615328/pubmed" id="26615328" target="_blank">26615328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24052132">
<a name="24052132"></a>Watanabe K. Current chemotherapeutic approaches for hepatoblastoma. <i>Int J Clin Oncol</i>. 2013;18(6):955-961.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/24052132/pubmed" id="24052132" target="_blank">24052132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12383808">
<a name="12383808"></a>WuDunn D, Cantor LB, Palanca-Capistrano AM, et al. A prospective randomized trial comparing intraoperative 5-fluorouracil vs mitomycin C in primary trabeculectomy. <i>Am J Ophthalmol</i>. 2002;134(4):521-528.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/12383808/pubmed" id="12383808" target="_blank">12383808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22481063">
<a name="22481063"></a>Xiang XJ, Liu YW, Zhang L, et al. A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. <i>Anticancer Drugs</i>. 2012;23(5):561-566. doi:10.1097/CAD.0b013e328350dd0d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/22481063/pubmed" id="22481063" target="_blank">22481063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19826418">
<a name="19826418"></a>Yoo C, Hwang JY, Kim JE, et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. <i>Br J Cancer</i>. 2009;101(10):1658-1663. doi:10.1038/sj.bjc.6605374<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/19826418/pubmed" id="19826418" target="_blank">19826418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20223786">
<a name="20223786"></a>Zaanan A, Costes L, Gauthier M, et al. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. <i>Ann Oncol</i>. 2010;21(9):1786-1793. doi:10.1093/annonc/mdq038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/20223786/pubmed" id="20223786" target="_blank">20223786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21425142">
<a name="21425142"></a>Zaanan A, Gauthier M, Malka D, et al; Association des Gastro Entérologues Oncologues. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. <i>Cancer</i>. 2011;117(7):1422-1428. doi:10.1002/cncr.25614<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-systemic-pediatric-drug-information/abstract-text/21425142/pubmed" id="21425142" target="_blank">21425142</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 15990 Version 335.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
